



Araştırma Makalesi / Research Article

Akciğer Skuamöz Hücreli Karsinomda Apolipoprotein B Gen Mutasyonu ve Promotor Metilasyon Durumunun Biyoinformatik Değerlendirilmesi

Bioinformatic Evaluation of Apolipoprotein B Gene Mutation and Promotor Methylation Status in Lung Squamous Cell Carcinoma

Mehmet Ali GÜL^{1*}, Durmuş AYAN^{2,3}

¹Amasya University, Faculty of Medicine, Department of Medical Biochemistry, Amasya, Türkiye

²Niğde Ömer Halisdemir University, Faculty of Medicine, Department of Medical Biochemistry, Niğde, Türkiye

³Niğde Ömer Halisdemir University, Research and Training Hospital, Medical Biochemistry, Niğde, Türkiye

Öz

Amaç: Literatürde apolipoproteinler ile kanser mortalitesi arasındaki bağlantıya dair yeterli kanıt bulunmamaktadır. Bu nedenle bu çalışmada Akciğer Skuamöz Hücreli Karsinomu (LUSC) ile ApoB genindeki mutasyonlar arasındaki olası ilişkinin araştırılması amaçlandı.

Gereç ve Yöntem: cBioPortal aracılığıyla TCGA veri tabanından toplam 469 kanser LUSC hastası dahil edildi. Genel sağkalımı (OS) değerlendirmek için Kaplan Meier Plott veritabanı kullanıldı. Promotör metilasyon seviyesi UALCAN veri tabanı tarafından belirlendi. Gen ekspresyon düzeyi GEPIA2 ile araştırıldı.

Bulgular: LUSC kohortunda ApoB geninde toplam 83 mutasyon tespit edildi. LUSC örneklerinde ApoB geni ekspresyon düzeyleri sağlıklı örneklerle göre düşüktü ancak bu istatistiksel olarak anlamlı değildi ($p>0.05$). LUSC kohortunda ApoB geninin ne yüksek ne de düşük ekspresyon seviyeleri OS ile ilişkili değildi. ApoB geninin promotör bölgesindeki hipometilasyon istatistiksel olarak anlamlıydı ($p<0.05$).

Sonuç: ApoB genindeki değişiklikler ile LUSC arasındaki ilişki tam olarak açık değildir. Bu nedenle ApoB'nin anti-kanser tedavilerinde potansiyel bir hedef veya biyobelirteç olarak değerlendirilmesinin prospektif çalışmalarla desteklenmesi gerektiğini düşünüyoruz.

Anahtar Kelimeler: Apolipoprotein B, Akciğer kanseri, Gen mutasyonu

Abstract

Aim: There is insufficient evidence in the literature about the link between apolipoproteins and cancer mortality. For this reason, the current study aimed to investigate the possible relationship between Lung Squamous Cell Carcinoma (LUSC) and mutations in the ApoB gene.



Material and Method: A total of 469 patients with cancer LUSC were included in the TCGA database via cBioPortal. The Kaplan Meier Plott database was used to evaluate overall survival (OS). The promoter methylation level was determined by the UALCAN database. The gene expression level was investigated by GEPIA2.

Results: A total of 83 mutations in the ApoB gene were detected in the LUSC cohort. ApoB expression levels were decreased in LUSC samples compared to healthy samples, but this was not statistically significant ($p>0.05$). Neither high nor low expression levels of the ApoB gene were associated with OS in the LUSC cohort. Hypomethylation in the promoter region of the ApoB gene was statistically significant ($p<0.05$).

Conclusion: The relationship between alterations in the ApoB gene and LUSC needs to be clarified. Therefore, prospective studies should support the evaluation of ApoB as a potential target or biomarker for anti-cancer treatments.

Keywords: Apolipoprotein B, Lung cancer, Gene mutation

İletişim adresi/Address for Correspondence:

Durmuş Ayan  <https://orcid.org/0000-0003-2615-8474>; Mehmet Ali Gül  <https://orcid.org/0000-0002-5849-0116>

Adres: Niğde Ömer Halisdemir Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Ana Bilim Dalı, Niğde, Türkiye

E-mail: durmusayan@hotmail.com

Telefon: +905336338185

Geliş Tarihi/Received:21 Mart 2024. Kabul Tarihi/Accepted:15 Nisan 2024. Çevrimiçi Yayın: Published Online: 30 Nisan 2024

INTRODUCTION

The incidence of lung cancer is increasing globally and remains the leading cause of cancer deaths. Lung cancer is an intricate and diverse condition distinguished by the irregular growth and varying rates of multiplication of cells in the lungs. There are various risk factors, but smoking is the predominant risk factor^{1,2}. Lung cancer presents diversity; the majority of lung cancers are non-small cell lung cancers, including squamous cell carcinoma, adenocarcinoma, and large cell carcinomas. Among these, adenocarcinoma stands out as the most prevalent form of lung cancer^{3,4}. ApoB serves a crucial function in the transport of lipoproteins and acts as the primary regulatory protein for many of them. While research on ApoB predominantly concentrates on cardiometabolic disorders, its connection to cancer remains less understood. However, heightened serum levels of ApoB have been linked to conditions like diabetes and metabolic syndrome, both of which have the potential to influence cancer development⁵.

Furthermore, there are studies suggesting that elevated levels of ApoB are associated with an increased risk of lung and colorectal cancer. At the same time, lower concentrations of ApoB are linked to a heightened risk of breast cancer⁶. In contrast, studies are showing that a low ApoA/ApoB ratio, i.e., high ApoB levels, is associated with an increased risk of lung and colorectal cancer⁷.

Studies investigating the association between ApoB and cancer mortality have controversial results. For this reason, we investigated the relationship between possible mutations and promoter methylation in the Apo B gene and Lung Squamous Cell Carcinoma (LUSC) by using some bioinformatics tools in this study.

MATERIAL AND METHODS

Working group design

This is a bioinformatic study. The present research utilized openly available data from The Cancer Genome Atlas (TCGA), a public repository accessible at <https://www.cancer.gov/tcga>. Ethical clearance has been obtained from the relevant authorities to include patients' data within this database. Researchers can freely access and download pertinent data for scientific investigation and

subsequent publication of findings. No ethical concerns or conflicting interests are associated with using this data. The LUSC dataset comprising 469 samples was acquired from the cBioPortal database, which offers open-access bioinformatics tools and data sourced from TCGA. The data retrieval occurred on August 10, 2023.

Evaluation of mutation

The mutation profile analysis of the ApoB gene in patients with LUSC was conducted using the cBioPortal web tool. This analysis utilized the OncoPrint interface feature provided by the tool. Additionally, various aspects, including amino acid position and localization, nucleotide change, cancer subtype, cancer stage, histological grade, and co-expression levels of selected genes, were evaluated using the cBioPortal web tool. Furthermore, the COSMIC database was consulted to confirm whether somatic mutations were present.

Survival analysis

The KM Plot (<https://kmplot.com/analysis/>) is an online resource offering gene expression and clinical data for analyzing the correlation between gene expressions and cancer survival rates⁸. This tool investigated the prognostic significance of ApoB gene expression levels in patients diagnosed with LUSC. Furthermore, the analysis encompassed the examination of overall survival (OS) outcomes among LUSC patients based on the expressions of associated genes.

Gene expression analysis

GEPIA2 (<http://gepia2.cancer-pku.cn/#index>) is an enhanced version of GEPIA, providing a web-based platform for comparing tumor tissues with normal tissues. In addition to existing features such as differential expression analyses, spectrogram plotting, correlation analyses, and patient survival analyses, GEPIA2 introduces new functionalities, including survival maps, isoform usage profiling, comparisons of uploaded expression data, and cancer subtype classifiers. It also allows users to customize analyses by uploading their RNA-seq data and comparing it with samples from TCGA and GTEx while enhancing some of the original functionalities⁹.

Methylation analysis

UALCAN is an interactive open-access web page for OMICS data analysis (<http://ualcan.Path.uab.edu/index.html>). This database is built on PERL-CGI and can be used at approximately 6000 gene methylation levels¹⁰. This study evaluated the promoter methylation level of the ApoB gene in the LUSC. Promoter region methylation levels of the ApoB gene were also examined in LUSC subtypes.

Statistical analysis

Data from the TCGA Pan-Cancer Atlas, obtained via cBioPortal, was utilized to gather patient information and statistically assess the mutation types within the ApoB gene. Additionally, statistical analyses were conducted using the GEPIA2 database, employing the one-way ANOVA test to evaluate differential expression. Survival analysis was performed using the KM plotter, with default settings, focusing on recurrence-free survival (RFS) and utilizing auto-best cutoff values and the J-best probe set. The optimal threshold for cutoff values, encompassing all possible values between the lower and upper quartiles, was determined, and the most suitable threshold was selected for analysis. A log-rank p-value of less than 0.05 was considered statistically significant.

RESULTS

Mutation profile

The cBioPortal web tool was used to analyze changes in ApoB protein in LUSC patients. Among 469 cases, 83 (17.7%) of LUSC patients had genetic changes in ApoB. The types of mutations encountered in the ApoB gene in LUSC are shown in Table 1. A missense mutation (73 mutations, 88%) was the most common type of change encountered in mutations in genes, while one splice (1.2%), one FS deletion (1.2%), and eight nonsense (9.6%) were found. The number of male and female patients with mutations was 63 (76%) and 20 (24%), respectively. Of the mutations analyzed, none were identified as originating from germ cells, except those classified as unknown mutations. All mutations, except those of unknown origin, were confirmed to be somatic.

In cases where missense mutations were observed in the examined genes, they led to phenotypic alterations in the protein. The nature of these changes varied depending on the type of missense mutation, whether conservative or nonconservative. Such mutations alter the mRNA's codon, encoding a different amino acid due to a change in base pairs. The functional consequences of these mutations may vary, potentially impairing or preserving the protein's function. Important mutations in the 100% conserved domains of the ApoB gene in the evolutionary process include the p. X302_splice mutation in the Vitellogenin_N domain, the p. S964* nonsense mutation in the DUF1081 domain, and the p. E4511* nonsense mutation in the Apolipoprotein B100 C-terminal domain. Information on amino acid changes and the effects of all other mutations are shown in Table 1.

Survival analysis

The KM Plot (<https://kmplot.com/analysis/>) analysis assessed OS. Data on the OS assessment are shown in Figure 1. When the OS results were evaluated, increased expression levels of the ApoB gene were found to be statistically associated with shorter OS ($p=0.79$).

Analyzes of promoter methylation level

DNA methylation plays a crucial role in modifying the genome epigenetically and is intricately linked to the cancer developmental process¹¹. UALCAN is a comprehensive, user-friendly, and interactive web resource for analyzing cancer OMICS data. It is built on PERL-CGI with high-quality graphics using JavaScript and CSS. UALCAN is designed 10. According to the results of the analysis using the UALCAN online tool to determine the DNA methylation level, the promoter methylation level of ApoB in LUSC tissues was lower (hypomethylation) compared to healthy tissues ($p=0.024$). However, this was not statistically significant. The results of this are shown in Figure 2.

Table 1: Demographic, clinical, and genetic data of patients with LUSC

No	Nucleotide Change	Amino Acid Position	Variation Type	Gender	Diagnosis Age	Duration	Exon/Intron/Splice	Tumor Stage	Metastasis Stage	Neoplasm Thissue Stage
M1	c.1356G>T	D452Y	MS	Male	81	Aspl00 C	N1	T2	M0	STAGE IIB
M2	c.1353G>T	E451* ⁺	NS	Male	72	Aspl00 C	N0	T2	M0	STAGE IIB
M3	c.1334G>A	E450R	MS	Male	69	NR0P	N0	T3	M0	STAGE IIB
M4	c.1398G>A	P499T	MS	Male	72	NR0P	N0	T2	M0	STAGE IIB
M5	c.1377C>G	L410Y	MS	Female	67	NR0P	N0	T1A	M0	STAGE IA
M6	c.1297G>A	S419*	NS	Female	66	NR0P	N0	T2A	M0	STAGE IIB
M7	c.1264G>A	H418V	MS	Female	75	NR0P	N0	T2	M0	STAGE IIB
M8	c.1212G>A	Q410R	MS	Female	66	NR0P	N1	T2	M0	STAGE IIB
M9	c.1230T>A	V408S	MS	Male	70	NR0P	N0	T1	M0	STAGE IIB
M10	c.1226G>T	K407N	MS	Male	44	NR0P	N1	T2A	M0	STAGE IIB
M11	c.1206G>A	E398R	MS	Male	61	NR0P	N0	T2	M0	STAGE IIB
M12	c.1167G>T	P392L	MS	Male	71	NR0P	N0	T1B	M0	STAGE IA
M13	c.1156G>T	W382V	MS	Male	74	NR0P	N0	T4	M0	STAGE IIB
M14	c.1136G>A	V376I	MS	Female	60	NR0P	N0	T2	M0	STAGE IIB
M15	c.1136G>A	E376R	MS	Female	73	NR0P	N0	T2	NA	STAGE IIB
M16	c.1133G>A	A376D	MS	Male	65	NR0P	N0	T2	M0	STAGE IIB
M17	c.1123G>C	P372A	MS	Male	72	NR0P	N0	T1	M0	STAGE IA
M18	c.1096G>A	G363D	MS	Male	73	NR0P	N0	T1	M0	STAGE IA
M19	c.1096G>A	F363S	MS	Male	54	NR0P	N0	T1A	M0	STAGE IIB
M20	c.1054G>A	N319K	MS	Male	70	NR0P	N0	T3	M0	STAGE IIB
M21	c.1044G>A	S314Y	MS	Male	60	NR0P	N0	T2A	M0	STAGE IIB
M22	c.1006C>A	A154D	MS	Male	67	NR0P	N0	T3B	M0	STAGE IIA
M23	c.0957G>T	F330*	NS	Male	65	NR0P	N2	T2	M0	STAGE IIB
M24	c.0875G>A	F319I	MS	Female	70	NR0P	N0	T2A	M0	STAGE IIB
M25	c.0746C>A	A313D	MS	Male	65	NR0P	N1	T4	NA	STAGE IIB
M26	c.562G>T	I324L	FS del	Male	69	NR0P	N0	T2	M0	STAGE IIB
M27	c.0867T>A	F319I	MS	Female	73	NR0P	N0	T2A	M0	STAGE IIB
M28	c.0583G>C	F316G	MS	Female	65	NR0P	N2	T2A	M0	STAGE IIA
M29	c.0264G>T	W308*	MS	Male	64	NR0P	N2	T2	M0	STAGE IIA
M30	c.0194G>T	N319K	MS	Male	70	NR0P	N0	T2A	M0	STAGE IIB
M31	c.0484G>C	S294T	MS	Male	70	NR0P	N0	T1A	M0	STAGE IIB
M32	c.0143G>T	E271*	NS	Male	64	NR0P	N0	T2	M0	STAGE IIB
M33	c.0074G>A	W268*	NS	Male	70	NR0P	N1	T2	M1	STAGE IV
M34	c.781G>C	V290I	MS	Male	70	NR0P	N0	T2	M0	STAGE IIB
M35	c.763G>C	V347I	MS	Male	67	NR0P	N0	T3B	M0	STAGE IIA
M36	c.755G>T	R252*	NS	Female	70	NR0P	N0	T1	M0	STAGE IA
M37	c.707G>C	D219H	MS	Male	68	NR0P	N0	T2A	M0	STAGE IIB
M38	c.705G>T	G215*	NS	Male	69	NR0P	N0	T2A	M0	STAGE IIB
M39	c.696G>A	F213R	MS	Male	58	NR0P	N1	T1	M0	STAGE IIA
M40	c.696G>T	F213D	MS	Male	65	NR0P	N0	T2A	M0	STAGE IIB
M41	c.693A>G	T204A	MS	Male	71	NR0P	N0	T2	M0	STAGE IIB
M42	c.0861A>T	H200I	MS	Male	63	NR0P	N1	T2	M0	STAGE IIB
M43	c.071G>T	S214I	MS	Male	66	NR0P	N2	T2	M0	STAGE IIB
M44	c.0272G>T	V200I	MS	Male	65	NR0P	N0	T2	M0	STAGE IIB
M45	c.0232G>C	E205G	MS	Female	62	NR0P	N1	T3	M0	STAGE IIA
M46	c.0184G>T	P204R	MS	Male	70	NR0P	N0	T3	M0	STAGE IIB
M47	c.0146C>G	P204R	MS	Male	70	NR0P	N0	T3	M0	STAGE IIB
M48	c.0774G>T	G195V	MS	Male	59	NR0P	N0	T3	M0	STAGE IIB
M49	c.0474A>T	T189S	MS	Male	59	NR0P	N2	T2	M0	STAGE IIA
M50	c.0416A>V	N186D	MS	Male	67	NR0P	N0	T4	M0	STAGE IIB
M51	c.0302A>G	K176G	MS	Male	71	NR0P	N0	T4	M0	STAGE IIB
M52	c.496C>A	T165A	MS	Male	71	NR0P	N0	T1A	M0	STAGE IIB
M53	c.407G>T	G161V	MS	Female	60	NR0P	N0	T3	M0	STAGE IIB
M54	c.471A>C	L157R	MS	Male	60	NR0P	N0	T2	M0	STAGE IIB
M55	c.439G>C	A146T	MS	Male	76	NR0P	N1	T4	M0	STAGE IIB
M56	c.438A>G	G146T	MS	Male	68	NR0P	N0	T2	M0	STAGE IIB
M57	c.432G>T	F143I	MS	Female	74	NR0P	N0	T2	M0	STAGE IIB
M58	c.419G>T	D138Y	MS	Male	63	NR0P	N0	T1B	M0	STAGE IA
M59	c.414A>G	D138I	MS	Male	74	NR0P	N0	T3	M0	STAGE IIB
M60	c.394G>T	F131D	MS	Male	68	NR0P	N0	T2	M0	STAGE IIB
M61	c.367G>T	V122I	MS	Male	60	NR0P	N1	T2	M0	STAGE IIB
M62	c.367G>A	H122G	MS	Male	78	NR0P	N0	T2	M0	STAGE IIB
M63	c.312A>G	G104D	MS	Female	76	NR0P	N0	T1	M0	STAGE IA
M64	c.302C>A	S102*	NS	Male	76	DEF101	N0	T1	M0	STAGE IIB
M65	c.289C>A	S94*	NS	Male	67	DEF101	N1	T1A	M0	STAGE IIA
M66	c.241G>T	E94K	MS	Female	69	DEF101	N1	T2	M0	STAGE IIB
M67	c.228G>C	M97S	MS	Male	69	DEF101	N0	T2	M0	STAGE IIB
M68	c.124G>T	D74V	MS	Male	69	DEF101	N0	T1A	M1B	STAGE IV
M69	c.120A>T	L73M	MS	Male	63	DEF101	N0	T1	M0	STAGE IA
M70	c.127G>T	G72M	MS	Female	70	DEF101	N0	T1	M0	STAGE IA
M71	c.106G>T	G67G	MS	Female	45	DEF101	N0	T3	M0	STAGE IIB
M72	c.1003G>T	R637W	MS	Male	78	NR0P	N0	T1	M0	NA
M73	c.179G>T	A598S	MS	Female	47	NR0P	N1	T1	M0	STAGE IIA
M74	c.175A>A	A578*	MS	Female	56	Vitellomun N	N1	T2B	M0	STAGE IIB
M75	c.168T>A	D556*	MS	Male	79	Vitellomun N	N0	T1	M0	STAGE IIB
M76	c.1426G>C	D477H	MS	Male	75	Vitellomun N	N0	T4	M0	STAGE IIB
M77	c.1318G>T	A448S	MS	Female	69	Vitellomun N	N0	T1	M0	STAGE IA
M78	c.1212G>T	P495S	MS	Male	67	Vitellomun N	N0	T1	M0	STAGE IIB
M79	c.1113G>T	T378I	MS	Male	64	Vitellomun N	N2	T2	M0	STAGE IIA
M80	c.0904A>G	X305 delins	Splice	Male	63	Vitellomun N	N0	T2A	M0	STAGE IIB
M81	c.077A>G	K207*	MS	Male	63	Vitellomun N	N0	T2	M0	STAGE I
M82	c.063G>T	T181*	MS	Male	66	Vitellomun N	N1	T1B	M0	STAGE IA
M83	c.301G>C	F101Q	MS	Male	74	Vitellomun N	N1	T1	M0	STAGE IIA

(OS) curve (using the Kaplan-Meier plotter). The red line represents the survival rate curve of patients with LUSC who expressed the gene, and the black line represents the survival rate curve of LUSC patients who did not express the gene.




Figure 2: The Promoter Methylation Level of ApoB gene in LUSC

no statistically significant distinction was observed in the expression levels of the examined genes between tumor tissue and normal tissue (p>0.05). In addition, expression levels according to LUSC subtypes (basal, classical, primitive, and secretory) and staging were not statistically different compared to healthy participants (Figure-3) (p>0.05).

DISCUSSION

In this study, 83 mutations were detected in 469 LUSC samples. Of these, 8 (9.7%) were nonsense mutations, 1 (1.2%) was splice mutation, 1 (1.2%) was frameshift deletion, and 73 (87.9%) were missense mutations. To the best of our knowledge, our study is the first to use bioinformatics tools to explore the association between the ApoB gene and LUSC.

Gene expression profiling interactive analysis results

According to the results of the comparison of expression levels in LUSC patients (n=486) and healthy participants (n=338) via ApoB (<http://gepia2.cancer-pku.cn/#index>) database,




Figure 1: Different expressions of the ApoB gene in LUSC patients in the overall survival




Figure 3: A- mRNA expressions of ApoB in LUSC (red) and normal breast tissues (gray). B- The expression level of the ApoB gene in LUSC is based on stages ($p=0.851$). C- The expression level of ApoB gene in LUSC based on major subclasses (basal, classical, primitive, secretory) * $p<0.05$

Apolipoproteins (Apo's) bind to lipids to form lipoproteins. Lipids are critical in creating the structural basis of biological membranes and signaling molecules¹². Apart from this, it is thought that Apo's are potential biomarkers in the diagnosis and prognosis of many malignancies such as lung cancer, gastric cancer, and colorectal cancer and that Apo's have a role in tumorigenesis and cancer progression¹³. Increasing evidence in recent years has shown that Apo's participate in classical cancer pathways involving PI3K/Akt, MAPK, and Wnt signaling¹³. The PI3K-Akt signaling pathway is a multifaceted regulatory network in human malignant tumors. It plays a pivotal role in governing tumor progression by regulating various aspects such as cell proliferation, genomic stability, and metabolism¹⁴. One of the genes with which the ApoB gene interacts in our LUSC cohort was the FGR gene, a member of the Src family of protein tyrosine kinases. The FGR gene is a protooncogene and increases the phosphorylation of phosphatidylinositol 3-kinase regulatory subunit (PIK3R1)¹⁵. This can show efficiency in PI3K/Akt regulation.

ApoB is located on chromosome 2p24.1 and encodes ApoB, the major apolipoprotein of chylomicrons and low-density lipoprotein (LDL)¹⁶. While LDL is known as the "bad cholesterol" for both heart and vascular disease, the functional role of cholesterol and its

transporter, ApoB, in cancer growth remains unclear. Increased cellular cholesterol levels can increase the proliferation and migration of cancer cells, possibly leading to tumor progression¹⁷. While studies argue that ApoB has severe effects on LDL and that increased lipid levels are associated with cancer deaths, including lung cancer, they say that ApoB may be a potential adjuvant method for future lung cancer treatments¹⁸. In this case, mutations that occur in the 100% conserved splice regions of the ApoB gene and affect the formation of truncated protein may affect lipid metabolism by creating severe effects on the protein function¹⁹. It is stated that truncated changes in the ApoB gene cause familial hypobetalipoproteinemia (FHBL), and these mutations increase continuously in different subjects²⁰. In addition, it is indicated that inactivating mutations in the ApoB gene disrupt VLDL particle metabolism, and triglyceride levels increase 3 times in cancer patients compared to healthy individuals²⁰. Lipid metabolism disorders play a vital role in the pathogenesis of squamous cell carcinoma. It is argued that disorders in lipid metabolism in lung squamous cell carcinoma may help understand the biological behavior of the tumor²¹. In the LUSC cohort, 9 mutations can cause the formation of truncated proteins.

The most important is the p. E4511* nonsense mutation in the ApoB100 C terminal domain. Nonsense mutation in this domain can result in the formation of a short and nonfunctional polypeptide chain. ApoB100 is essential in the assembly and secretion of triglyceride-rich lipoproteins and lipids transport²². In this case, in addition to defective lipid transport, it is possible to experience problems in the secretion of triglyceride-rich lipoproteins. Apart from this mutation, mutations in the gene or its regulatory region can cause diseases that affect ApoB levels, ligand-defective ApoB-induced hypercholesterolemia, normotriglyceridemic hypobetalipoproteinemia, and hypobetalipoproteinemia²³.

In addition, in cases where mutations can form this truncated protein, there are mutations known as recurrent hotspots (statistically significant) in different genes. The p.S964 nonsense mutation mainly accompanies the X51_splice change in the CDKN2A gene. The CDKN2A gene encodes two proteins, p16INK4A and p14ARF, which regulate cell growth and survival. Such a mutation occurring

in this gene may lead to decreased binding to CDK4 and CDK6, resulting in an inability to inhibit the cell cycle^{24,25}. In addition, p.V155F missense mutation in the KEAP1 gene occurred in the case with p.E4511* nonsense mutation in the ApoB100 C terminal region. This change is a recurrent hotspot located in the KEAP1 intervening region domain. With this mutation, the binding affinity of KEAP1 to the Nuclear Factor Erythroid-2-Like 2 (Nrf2) transcription factor, a master regulator of the antioxidant response, was increased²⁶. Nrf2, which mediates the activation of cell-protective genes when released under normal conditions, may not be able to fulfill its task with the resulting mutation fully^{26,27}.

Another important recurrent hotspot change is the p.L861Q missense mutation in the EGFR gene in a case with p.W2686* nonsense mutation. This mutation occurs in the EGFR tyrosine kinase domain and has an oncogenic feature. Apart from these, TP53 p.V274F missense mutation (related ApoB mutation p.E2715* nonsense), TP53 p. G244V missense mutation (related ApoB mutation p. I3228Lfs*38 FS del), TP53 p. C176Y missense mutation and BRAF p. G469R missense mutation (related ApoB mutation p. E3303* nonsense) are oncogenic and may have a negative effect on tumor development in addition to changes in the ApoB gene. In addition, studies suggest that mutations in the ApoB gene are not directly oncogenic. Still, ApoB gene inactivation may be associated with overexpression of oncogenic regulators that support cancer development and downregulation of tumor suppressors^{12,28}. This may suggest that ApoB may be involved in regulating the expression of oncogenic regulators and tumor suppressors and that its inactivation may contribute to the development and progression of cancer²⁸. The fact that the most common recurrent hotspot mutation encountered in the above cases with the ApoB gene mutation is in the tumor suppressor gene TP53 may suggest that there may be a condition associated with the inactivation of the ApoB gene.

Formation of VLDL with ApoB-100 requires much energy. In tumor formation (the process of tumor formation), much energy is needed to support the rapid growth and proliferation of cancer cells. In this case, it is predicted that cancer cells may prefer ApoB-inactivating mutations. Because less ApoB-100 production

will result in more energy for cancer metabolism¹², this hypothesis may suggest that inactivating mutations in the ApoB gene may promote cancer growth and progression by providing cancer cells with more energy.

In lung cancer, high ApoB levels have been associated with an increased incidence⁶. The results remain controversial, as lipoproteins containing ApoB have been implicated as risk factors for tumorigenesis. It is also thought that ApoB levels may be associated with a greater risk of cancer death⁵. Neither high nor low expression levels of the ApoB gene were associated with OS in the LUSC cohort. This may mean that changes in the ApoB gene do not affect survival from diagnosis (or initiation of treatment) to death.

The bioinformatics study states that the response to immune checkpoint inhibitors is weaker in cases with high ApoB expression levels²⁹. It has been determined that ApoB is frequently mutated in hepatocellular cancer (HCC) patients and mutations in this protein account for almost 10% of all mutations observed in this patients³⁰. The study investigating ApoB gene levels in HCC reported that ApoB gene ablation may be highly associated with poor clinical outcomes in HCC and proliferation of HCC cells²⁸. While it has been reported that decreasing ApoB has a vital role in the development of breast cancer,³¹ data from another study found that rs693 and rs1042031 polymorphisms in the ApoB gene increase the risk of breast cancer³². In addition, it was emphasized that the measurement of decreased ApoA1 levels and increased ApoB levels in patients with early-stage gastric cancer is a potential biomarker in the progression of the disease³³. While the data on ApoB in different cancer types are in this direction, the expression levels of the ApoB gene in tumor tissue in the LUSC cohort and LUSC subtypes (basal, classical, primitive, and secretory) were lower than in healthy tissue, but this was not statistically significant. In this case, hypomethylation in the promoter region of the ApoB gene in the LUSC cohort may not have had a severe effect on ApoB gene expression levels. Moreover, in the first scenario, this cause of hypomethylation may be the result of posttranslational modifications. In the second scenario, it could be the result of global DNA hypomethylation. Global DNA hypomethylation is a hallmark of human cancer, but its functional consequences remain unclear. Gene expression

and DNA methylation are two important molecular processes that can be altered in LUSC, a type of lung cancer³⁴. There are associations between DNA methylation alterations and various factors such as the specific types of lung cancer, mutations in genes known to drive cancer growth (such as KRAS, EGFR, and TP53), and major risk factors like sex, smoking status, and race/ethnicity³⁵. By better understanding how DNA methylation is regulated and how different risk factors influence it, we can gain valuable insights into the process of carcinogenesis (the development of cancer). This knowledge can help develop cancer prevention strategies and personalized treatments targeting specific DNA methylation alterations.

CONCLUSIONS

Although severe mutations in the LUSC cohort impair ApoB gene function, the relationship between epigenetic changes in the ApoB gene, gene expression levels, OS, and LUSC is unclear. Therefore, ApoB needs to be validated for future studies to be a potential target for anti-cancer therapies and to evaluate ApoB mutation as a biomarker for cancer risk and prognosis. We also think the relationship between methylation and lung cancer should be investigated in depth with population-based studies. In this context, our study will shed light on future research.

Etik Onay: Bu çalışmada kullanılan veriler TCGA kamu veri tabanından elde edildiğinden etik onaya gerek duyulmamaktadır.

Çıkar Çatışması: Bu çalışma ile ilgili olarak yazarların çıkar çatışması bulunmamaktadır.

Finansal Destek: Bu çalışma için herhangi bir kurum ya da firmadan maddi ve/veya manevi herhangi bir destek alınmamıştır.

Ethical Approval: The data used in this study were obtained from the public database TCGA. Therefore, ethical approval was not required.

Conflict of Interest: The authors have no conflict of interest regarding this study.

Financial Support: No financial and/or moral support was received from any institution or company for this study.

REFERENCES

1. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. *Clin Chest Med*, 2020;41(1):1-24. <https://doi.org/10.1016/j.ccm.2019.10.001>
2. Zou Y, Zheng H, Yue N, Yang Y, Wen Q, Fan S. New insights into the important roles of phase separation in the targeted therapy of lung cancer. *Cell Biosci*, 2023;13(1):150. <https://doi.org/10.1186/s13578-023-01101-8>

3. Bechtel JJ, Petty TL, Saccomanno G. Five year survival and later outcome of patients with X-ray occult lung cancer detected by sputum cytology. *Lung Cancer*, 2000;30(1):1-7. [https://doi.org/10.1016/s0169-5002\(00\)00190-2](https://doi.org/10.1016/s0169-5002(00)00190-2)
4. Merino Salvador M, Gomez de Cedron M, Moreno Rubio J, Falagán Martínez S, Sánchez Martínez R, Casado E, et al. Lipid metabolism and lung cancer. *Crit Rev Oncol Hematol*, 2017; 112:31-40. <https://doi.org/10.1016/j.critrevonc.2017.02.001>
5. Mazidi M, Katsiki N, Mikhailidis DP, Radenkovic D, Pella D, Banach M. Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations. *J Clin Med*, 2020; 9(1). <https://doi.org/10.3390/jcm9010170>
6. Borgquist S, Butt T, Almgren P, Shiffman D, Stocks T, Orho-Melander M, et al., Apolipoproteins, lipids and risk of cancer. *Int J Cancer*, 2016;138(11):2648-56. <https://doi.org/10.1002/ijc.30013>
7. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*, 2018;392(10159):1736-1788. [https://doi.org/10.1016/S0140-6736\(18\)32203-7](https://doi.org/10.1016/S0140-6736(18)32203-7)
8. Menyhart O, Nagy A, Gyorffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. *R Soc Open Sci*, 2018;5(12):181006. <https://doi.org/10.1098/rsos.181006>
9. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. *Nucleic Acids Res*, 2019;47(W1): W556-W560. <https://doi.org/10.1093/nar/gky311>
10. Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al., UALCAN: An update to the integrated cancer data analysis platform. *Neoplasia*, 2022;25:18-27. <https://doi.org/10.1016/j.neo.2022.01.001>
11. Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. *Trends Genet*, 2021;37(11):1012-1027. <https://doi.org/10.1016/j.tig.2021.05.002>
12. Delk S, Chattopadhyay A, Escola-Gil JC, Fogelman AM, Reddy ST. Apolipoprotein mimetics in cancer. *Semin Cancer Biol*, 2021;73:158-168. <https://doi.org/10.1016/j.semcancer.2020.11.002>
13. He Y, Chen J, Ma Y, Chen H. Apolipoproteins: New players in cancers. *Front Pharmacol*, 2022; 13: 1051280. <https://doi.org/10.3389/fphar.2022.1051280>
14. Sun B, Zhao H. Bioinformatics Analysis of Differential Gene and MicroRNA Expression in Lung Adenocarcinoma: Genetic Effects on Patient Prognosis, as Indicated by the TCGA Database. *Cancer Inform*, 2022;21:11769351221082020. <https://doi.org/10.1177/11769351221082020>
15. Zhu Y, Yan C, Wang X, Xu Z, Lv J, Xu X, et al., Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy. *Cancer Biol Ther*, 2022;23(1):104-111. <https://doi.org/10.1080/15384047.2021.2011643>
16. Henderson R, O'Kane M, McGilligan V, Watterson S. The genetics and screening of familial hypercholesterolaemia. *J Biomed Sci*, 2016;23:39. <https://doi.org/10.1186/s12929-016-0256-1>
17. Ding X, Zhang W, Li S, Yang H. The role of cholesterol metabolism in cancer. *Am J Cancer Res*, 2019;9(2):219-227.

18. Deng W, Liu H, Luo S, Clarke J, Glass C, Su L, et al., APOB Genotypes and CDH13 Haplotypes in the Cholesterol-Related Pathway Genes Predict Non-Small Cell Lung Cancer Survival. *Cancer Epidemiol Biomarkers Prev*, 2020;29(6): 1204-1213. <https://doi.org/10.1158/1055-9965.EPI-19-1262>.
19. Whitfield AJ., Barrett PHR, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the APOB gene. *Clin Chem*, 2004;50(10):1725-32. <https://doi.org/10.1373/clinchem.2004.038026>.
20. Cefalù AB, Pirruccello JP, Noto D, Gabriel S, Valenti V, Gupta N, et al., A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. *Arterioscler Thromb Vasc Biol*, 2013;33(8):2021-5. <https://doi.org/10.1161/ATVBAHA.112.301101>.
21. Zeng W, Zheng W, Hu S, Zhang J, Zhang W, Xu J, et al., Application of Lipidomics for Assessing Tissue Lipid Profiles of Patients With Squamous Cell Carcinoma. *Technol Cancer Res Treat*, 2021;20:15330338211049903. <https://doi.org/10.1177/15330338211049903>.
22. Guevara J, Romo J, Hernandez E, Guevara NV. Identification of Receptor Ligands in Apo B100 Reveals Potential Functional Domains. *Protein J*, 2018;37(6):548-571. <https://doi.org/10.1007/s10930-018-9792-8>.
23. Khalil YA, Rabès J-P, Boileau C, Varret M. APOE gene variants in primary dyslipidemia. *Atherosclerosis*, 2021;328:11-22. <https://doi.org/10.1016/j.atherosclerosis.2021.05.007>.
24. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. *Mol Med*, 1997;3(1):5-20. <https://doi.org/10.1007/BF03401664>.
25. Chan SH, Chiang J, Ngeow J. CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition. *Hered Cancer Clin Pract*, 2021; 19(1):21. <https://doi.org/10.1186/s13053-021-00178-x>.
26. Hast BE, Cloer EW, Goldfarb D, Li H, Siesser PF, Yan F, et al. Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination. *Cancer Res*, 2014;74(3):808-17. <https://doi.org/10.1158/0008-5472.CAN-13-1655>.
27. Akın-Balı DF, Aktas SH, Unal MA, Kankılıc T. Identification of novel Nrf2/Keap1 pathway mutations in pediatric acute lymphoblastic leukemia. *Pediatr Hematol Oncol*, 2020;37(1):58-75. <https://doi.org/10.1080/08880018.2019.1682090>.
28. Lee G, Jeong YS, Kim DW, Kwak MJ, Koh J, Joo EW, et al. Clinical significance of APOB inactivation in hepatocellular carcinoma. *Exp Mol Med*, 2018;50(11):1-12. <https://doi.org/10.1038/s12276-018-0174-2>.
29. Hu Z, Zheng Y, Zheng J, Wang Y, Liao J, Lu X, et al. Serum cholesterol-riched apolipoprotein-B (apoB) containing lipoproteins predict the response to immune checkpoints inhibitors (ICIs) in non-small cell lung cancer (NSCLC) : A retrospective analysis. 2022, Research Square. <https://doi.org/10.21203/rs.3.rs-1749981/v2>.
30. Nault J-C, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, et al. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. *Hepatology*, 2020;71(1):164-182. <https://doi.org/10.1002/hep.30811>.
31. Han C-Z, Du L-L, Jing J-X, Zhao X-W, Tian F-G, Shi J, et al. Associations among lipids, leptin, and leptin receptor gene Gin223Arg polymorphisms and breast cancer in China. *Biol Trace Elem Res*, 2008;126(1-3):38-48. <https://doi.org/10.1007/s12011-008-8182-z>.
32. Liu X, Wang Y, Qu H, Hou M, Cao W, Ma Z. et al, Associations of polymorphisms of rs693 and rs1042031 in apolipoprotein B gene with risk of breast cancer in Chinese. *Jpn J Clin Oncol*, 2013;43(4):362-8. <https://doi.org/10.1093/jjco/hyt018>.
33. Kimak E, Nurczyk K, Skoczylas T, Duma D, Gieroba R, Solski J. et al. Fibroblast growth factor 21, epidermal growth factor receptor, interleukin 6, myeloperoxidase, lipid hydroperoxide, apolipoproteins A-I and B, as well as lipid and lipoprotein ratios as diagnostic serum biomarkers for gastric cancer. *Pol Arch Intern Med*, 2019;129(7-8):559-562. <https://doi.org/10.20452/pamw.14836>.
34. Heryanto YD, Katayama K, Imoto S. Analyzing integrated network of methylation and gene expression profiles in lung squamous cell carcinoma. *Sci Rep*. 2022;22;12(1):15799. <https://doi.org/10.1038/s41598-022-20232-5>.
35. Hoang PH, Landi MT. DNA Methylation in Lung Cancer: Mechanisms and Associations with Histological Subtypes, Molecular Alterations, and Major Epidemiological Factors. *Cancers (Basel)*. 2022;15;14(4):961. <https://doi.org/10.3390/cancers14040961>.